Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Total Liabilities (2016 - 2025)

Gsk has reported Total Liabilities over the past 11 years, most recently at $60.1 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $60.1 billion for Q4 2025, up 0.92% from a year ago — trailing twelve months through Dec 2025 was $60.1 billion (up 0.92% YoY), and the annual figure for FY2025 was $60.1 billion, up 0.92%.
  • Total Liabilities for Q4 2025 was $60.1 billion at Gsk, up from $59.5 billion in the prior quarter.
  • Over the last five years, Total Liabilities for GLAXF hit a ceiling of $77.9 billion in Q4 2021 and a floor of $57.4 billion in Q4 2023.
  • Median Total Liabilities over the past 5 years was $59.5 billion (2024), compared with a mean of $62.7 billion.
  • Biggest five-year swings in Total Liabilities: decreased 24.6% in 2022 and later grew 3.79% in 2024.
  • Gsk's Total Liabilities stood at $77.9 billion in 2021, then decreased by 24.6% to $58.7 billion in 2022, then decreased by 2.3% to $57.4 billion in 2023, then rose by 3.79% to $59.5 billion in 2024, then increased by 0.92% to $60.1 billion in 2025.
  • The last three reported values for Total Liabilities were $60.1 billion (Q4 2025), $59.5 billion (Q4 2024), and $57.4 billion (Q4 2023) per Business Quant data.